

Mouse anti-Human CK19 / CYFRA21-1 Monoclonal Antibody | anti-CK19 / CYFRA21-1 antibody

Monoclonal Anti-CK19 / CYFRA21-1 (Capture Ab)

CATALOG # AAA59100	HOST Mouse	REACTIVITY Human	APPLICATIONS ELISA, Western Blot
------------------------------	----------------------	----------------------------	--

PRODUCT SYNONYMS

CK19 / CYFRA21-1; Monoclonal Antibody; Monoclonal Anti-CK19 / CYFRA21-1 (Capture Ab); anti-CK19 / CYFRA21-1 antibody

PRODUCT SPECIFICATIONS

Host	Mouse
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Clone Number	D5
Specificity	It specifically recognizes the human CK19 / CYFRA21-1, and may cross react with CK20, CK8 & CK18.
Purity/Purification	>95% by HPLC & SDS-PAGE Protein A or G purified and supplied in 0.01 M PBS (pH7.4) & 0.15 M NaCl without preservative.
Form/Format	Liquid
Applicable Applications for anti-CK19 / CYFRA21-1 antibody	CLIA (Chemiluminescence Immunoassay), ELISA, WB (Western Blot)
Immunogen	40 KDa of Keratin 19 protein.
Preparation and Storage	Aliquot and store at -20°C for long term (at least one year). Avoid repeated freeze and thaw cycles.

ADDITIONAL INFORMATION

Related Product Information for anti-CK19 / CYFRA21-1 antibody	<p>Keratin, type I cytoskeletal 19 also known as cytokeratin-19 (CK-19) or keratin-19 (K19) is a 40 kDa protein that in humans is encoded by the KRT19 gene. KRT19 is also known as Cyfra 21-1. The usefulness of serum CYFRA 21-1 (cytokeratin-19 fragments) in monitoring the recurrence of breast cancer and in evaluating therapeutic effects. Serum CYFRA 21-1 may be a reliable marker of recurrence or therapeutic efficacy. The serum level of Cyfra21-1 was a useful biomarker for identification of nonsmall cell lung cancer (NSCLC) as well. The serum cytokeratin 19 fragment 21.1 (CYFRA21-1) level was elevated in nasopharyngeal carcinoma (NPC) and can function as a biomarker for detection and monitoring of NPC. After analyzing NPC group and healthy control group, Song XM et al concluded that the serum CYFRA21-1 level could be a reliable and effective biomarker for the detection and monitoring of NPC tumor progression.</p>
--	--

References

1. Schweizer J, Bowden PE, Coulombe PA, Langbein L, Lane EB, Magin TM, Maltais L, Omary MB, Parry DA, Rogers MA, Wright MW (July 2006). "New consensus nomenclature for mammalian keratins". J Cell Biol 174 (2): 169–74.
2. Nakata B, Takashima T, Ogawa Y, Ishikawa T, Hirakawa K. Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer. Br J Cancer. 2004 Aug 31;91(5):873-8.
3. Cui C, Sun X, Zhang J, Han D, Gu J. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis. J Cancer Res Ther. 2014 Nov;10 Suppl:C131-4.
4. Song XM, Wang SZ, Wang ZJ, Cao WJ, L J, Chen F. Serum CYFRA21-1 as an effective tumor biomarker for patients with nasopharyngeal carcinoma. Neoplasma. 2015;62(1):124-9.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com

Online datasheet: <https://stage.aaabiotech.com/monoclonal/ck19-cyfra21-1-antibody-clone-d5-chemiluminescence-immunoassay-western-blot-elisa/59100>